Whether it’s Ozempic, Wegovy, or Mounjaro, many people have recently turned to pharmaceutics to help trim down.
Many of these drugs were originally designed to help people with type 2 diabetes, but have since been adopted by those hoping to have a helping hand with shedding a few pounds.
Often administered via weekly injectables, they work by suppressing appetite and increasing the sense of fullness.
Advert
As with many medications, there’s always a risk of certain side effects, as well as concerns around the longer term impact that the drugs might have.
But a number of high-profile celebs haven’t been put off, and cannot sing the praises of the injections loudly enough.
While many people were talking about similar drug Ozempic last year, Adam Lambert admitted he’d actually made the switch to Mounjaro.
Advert
"I'm dropping some tea on you guys right now,” he told fans on Instagram.
“I've been on Mounjaro for the last I think, what, eight months?"
The star said he felt ‘amazing’, adding: “I still eat, but I eat lighter, and I eat less, and I know that there's a lot of chatter about 'Oh, you're taking it away from diabetes patients'.”
Lambert had a clear stance on what his critics had to say, saying bluntly: "I mean, quite frankly, that's the pharmaceutical industry's issue, not mine. They need to keep up with production."
Advert
The singer was previously on Ozempic, but decided to change to Mounjaro after experiencing severe side effects.
"When I switched to Mounjaro, a lot of those symptoms went away and I had hardly any side effects and I feel incredible," he said.
"I feel better, I feel more confident. I feel like my actual body feels better, like my digestive system feels more regulated."
Advert
Ozempic is only officially used to treat type 2 diabetes. It is not a legitimate weight loss management drug and is not FDA-approved for this use.
Mounjaro, meanwhile, has now been approved for weight loss management, as well as diabetes, as it helps lower blood sugar levels.
A key difference between the two is that Mounjaro – which contains tirzepatide - targets both the GLP-1 and GIP receptors, instead of just the GLP-1 receptor, which are two appetite-regulating hormones.
Jess Hardiman